

Oramed gets Japanese Patent for GLP-1 analog capsule

24 July 2018 | News

A Japanese Intellectual Property Office has publicized its intent to grant a patent titled, "Methods and Compositions for Oral Administration of Exenatide"



Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. A clinical-stage pharmaceutical company announced that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide." The patent covers Oramed's proprietary invention of an oral glucagon-like peptide-1 (GLP-1) analog.

Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).

The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).